/Investor DB

Innovation Endeavors — 2020 Investments

2 investments dated 2020 · listed companies and verified rows first · show all

Dewpoint Therapeuticsdewpointx.comin𝕏Sep 2020✓ verified

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)

Co-investorsARCH Venture PartnersEcoR1 CapitalGeneral CatalystSamsara BioCapital6 Dimensions CapitalLeaps by Bayer+6 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

InsidePacket

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.